

# CHEST<sup>®</sup>

THE CARDIOPULMONARY  
AND CRITICAL CARE JOURNAL

FOR PULMONOLOGISTS, CARDIOLOGISTS, CARDIOTHORACIC SURGEONS,  
CRITICAL CARE PHYSICIANS, AND RELATED SPECIALISTS

## Managing Oral Anticoagulant Therapy

Jack Ansell, Jack Hirsh, James Dalen, Henry Bussey, David Anderson, Leon Poller,  
Alan Jacobson, Daniel Deykin and David Matchar

*Chest* 2001;119;22-38

DOI: 10.1378/chest.119.1\_suppl.22S

**This information is current as of June 29, 2005**

The online version of this article, along with updated information and services, is  
located on the World Wide Web at:

[http://www.chestjournal.org/cgi/content/full/119/1\\_suppl/22S](http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S)

CHEST is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright 2005 by the American College of Chest Physicians, 3300 Dundee Road, Northbrook IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder. ISSN: 0012-3692.

A M E R I C A N C O L L E G E O F  
 C H E S T  
P H Y S I C I A N S

# Managing Oral Anticoagulant Therapy

Jack Ansell, MD; Jack Hirsh, MD, FCCP;  
James Dalen, MD, FCCP; Henry Bussey, PharmD;  
David Anderson, MD; Leon Poller, MD; Alan Jacobson, MD;  
Daniel Deykin, MD; and David Matchar, MD

**Abbreviations:** AMS = anticoagulation management service; CV = coefficient of variation; INR = international normalized ratio; IRP = international reference preparation; ISI = international sensitivity index; LMWH = low-molecular-weight heparin; NS = not significant; POC = point of care; PSM = patient self-management; PST = patient self-testing; PT = prothrombin time; SC = subcutaneous; TTR = time in therapeutic range; UC = usual care

(*CHEST* 2001; 119:22S–38S)

Several important developments in the last 2 decades have improved clinical outcomes with oral anticoagulation therapy and have led to an appropriate increase in the use of this therapy by improving its safety. These developments include defining the appropriate indications for oral anticoagulation through the results of large randomized trials,<sup>1,2</sup> identifying the optimal therapeutic range and reporting format (*ie*, international normalized ratio [INR]) to maximize safety and effectiveness,<sup>3–16</sup> and managing the dose of therapy to achieve the maximal time in therapeutic range (TTR).<sup>17–19</sup> The intensity of therapy and the TTR are two of the most important determinants of therapeutic effectiveness and of reducing hemorrhagic risk. Ideally, the INR should be kept in the therapeutic range most of the time, but many factors influence the attainment of this goal. These include physiologic and pharmacologic factors, such as interacting drugs or illnesses that affect the pharmacokinetics or pharmacodynamics of warfarin, dietary or GI factors that affect the availability of vitamin K<sub>1</sub>, or physiologic factors that affect the synthetic or metabolic fate of the vitamin K-dependent coagulation factors. Patient-specific factors such as adherence to a therapeutic plan are also important. Last, the physician's ability to make appropriate dosing and follow-up decisions will have a profound impact, if such decisions are incorrect. The comprehensive management of these variables requires a knowledgeable provider, an organized system of follow-up, reliable prothrombin time (PT) monitoring, and good patient communication and education. This article focuses on dosing management and models of care, and it reviews the evidence that indicates that an organized approach to anticoagulant management leads to better outcomes.

## PRACTICAL DOSING

### Initiation and Maintenance Dosing

Following the administration of warfarin, an observable anticoagulant effect occurs within 2 to 7 days, depending

on the dose administered.<sup>20,21</sup> When a rapid effect is required, heparin should be given concurrently with warfarin for at least 4 days. The common practice of initiating warfarin therapy with a loading dose is unnecessary in most patients, and commencing with an average maintenance dose of 5 mg warfarin usually results in an INR of 2.0 in 4 or 5 days.<sup>21</sup> Heparin treatment is usually discontinued when the INR has been in the therapeutic range on two measurements made at least 24 h apart. If treatment is not urgent (*eg*, chronic stable atrial fibrillation), treatment can be commenced out-of-hospital with an anticipated maintenance dose of 4 to 5 mg/d, which usually achieves a therapeutic anticoagulant effect in about 5 days, although a stable INR may take longer to achieve. The fear of creating a hypercoagulable state in patients with unrecognized protein C deficiency who are not simultaneously receiving heparin has not been substantiated. However, in patients with a known protein C deficiency or other thrombophilic state, it would be prudent to begin administering heparin before or at the same time as warfarin. There is room for flexibility in selecting a starting dose of warfarin. Some clinicians prefer to use a larger starting dose (*eg*, 7.5 to 10 mg) if there is urgency in obtaining a therapeutic INR. Additionally, starting doses < 5 mg might be appropriate in the elderly, in patients with impaired nutrition or liver disease, and in patients at high risk for bleeding.

PT monitoring is usually performed daily until the therapeutic range has been achieved and maintained for at least 2 consecutive days, then it is monitored two or three times weekly for 1 to 2 weeks, then less often, depending on the stability of PT results. If the PT response remains stable, the frequency of testing can be reduced to intervals as long as every 4 weeks, although there is growing evidence to suggest that more frequent testing will lead to greater TTR (see below). If adjustments to the dose are required, then the cycle of more frequent monitoring is repeated until a stable dose response again is achieved.

### Anticoagulation Therapy in the Elderly

The physician should be aware of the factors that influence the response to anticoagulation therapy in the elderly. The dose required to maintain a therapeutic range for patients > 60 years of age has been shown to decrease with increasing age,<sup>22–24</sup> possibly because the clearance of warfarin decreases with age.<sup>25,26</sup> Older patients are also more likely to have a greater number of other factors that might influence INR stability or might influence the risk of bleeding, such as a greater number of other medical conditions or concurrent drug use.<sup>22</sup> Consequently, it is advisable to monitor older patients more carefully in order to maximize their time in the therapeutic range.<sup>27</sup>

## MANAGEMENT OF NONTHERAPEUTIC INRS

Some patients receiving long-term warfarin therapy are difficult to manage because they have unexpected fluctuations in dose response.<sup>28</sup> These unexpected fluctuations could be due to a number of variables, including inaccuracy in PT testing, changes in vitamin K<sub>1</sub> intake (*ie*, increased or decreased vitamin K<sub>1</sub> in the diet), changes in

Correspondence to: Jack E. Ansell, MD, Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118; e-mail: jack.ansell@bmc.org

vitamin K<sub>1</sub> or warfarin absorption (*eg*, GI factors or drug effects), changes in warfarin metabolism (*eg*, liver disease or drug effects), changes in vitamin K<sub>1</sub>-dependent coagulation factor synthesis or metabolism (*eg*, liver disease, drug effects, or other medical conditions), other effects of undisclosed concomitant drug use, or patient compliance issues (*eg*, surreptitious self-medication, missed doses, miscommunication about dose adjustment, etc).

Three approaches can be taken to reduce an elevated INR. The first is to stop warfarin therapy; the second is to administer vitamin K<sub>1</sub>; the third, and most rapidly effective, is to infuse fresh frozen plasma or prothrombin concentrate, although the latter may be difficult to obtain and may carry the risk of virus transmission. The choice of approach is based largely on clinical judgment, since to our knowledge, there have been no randomized trials using clinical end points to compare these strategies. When warfarin therapy is interrupted, White and associates<sup>29</sup> found that it takes about 4 to 5 days for the INR to return to the normal range in patients whose INRs are between 2.0 and 3.0. After treatment with oral vitamin K<sub>1</sub>, the INR declined substantially within 24 h. Since the absolute daily risk of bleeding is low even when the INR is excessively prolonged, many physicians manage patients with INR values of 4.0 to 10.0 by stopping warfarin therapy and monitoring more frequently,<sup>30</sup> unless the patient is at an intrinsically high risk of bleeding or bleeding has already developed. Ideally, vitamin K<sub>1</sub> should be administered in a dose that will quickly lower the INR into a safe but not subtherapeutic range without causing resistance once warfarin therapy is reinstated<sup>31</sup> or without exposing the patient to the risk of anaphylaxis. High doses of vitamin K<sub>1</sub>, though effective, may lower the INR more than is necessary and may lead to warfarin resistance for up to a week. Vitamin K<sub>1</sub> can be administered by IV, subcutaneous, or oral routes. IV injection may be associated with anaphylactic reactions,<sup>32</sup> and there is no definitive evidence that this serious, but rare, complication can be avoided by using low doses. The response to subcutaneous vitamin K<sub>1</sub> may be unpredictable and sometimes delayed.<sup>33,34</sup> Recent studies confirm earlier reports that oral administration is predictably effective and has the advantages of safety and convenience over parenteral routes.

In 1993, Pengo and associates<sup>35</sup> confirmed earlier observations<sup>36,37</sup> of the effectiveness of oral vitamin K<sub>1</sub> by a randomized trial demonstrating that 2.5 mg oral vitamin K<sub>1</sub> was more effective than withholding warfarin for correcting the INR to < 5.0 at 24 h. Weibert and associates,<sup>38</sup> in a retrospective cohort study, evaluated the effectiveness of a 2.5-mg dose of oral vitamin K<sub>1</sub> for reversing an excessive warfarin effect in 81 patients with an INR of > 5.0. Ninety percent of the patients achieved an INR of < 5.0, and only 17% developed an INR of < 2.0. An INR of < 5.0 was achieved in 48 h in all patients whose initial INRs were < 9.0. However, a dose of 2.5 mg oral vitamin K<sub>1</sub> failed to lower the INR to < 5.0 in five of eight patients (63%) whose initial INRs were > 9.0. In patients with excessively prolonged INR values, oral vitamin K<sub>1</sub>, 5 mg, more reliably lowered the INR to < 5.0 within 24 h than simply withholding warfarin therapy. Crowther and associates<sup>39</sup> carried out a prospective cohort

study of 62 patients treated with warfarin who had INR values between 4.0 and 10.0. The next dose of warfarin was omitted, and vitamin K<sub>1</sub>, 1 mg, was administered orally. After 24 h, the INR was lowered in 59 patients (95%), fell to < 4.0 in 53 patients (85%), and to < 1.9 in 22 patients (35%). No patients developed resistance when warfarin therapy was resumed. These observations indicate that oral vitamin K<sub>1</sub> is effective in low doses for reducing the INR in patients treated with warfarin. A dose range of 1.0 to 2.5 mg is effective when the INR is between 5.0 and 9.0, but larger doses (5 mg) are required to correct INRs > 9.0.

Oral vitamin K<sub>1</sub> is the treatment of choice, but vitamin K<sub>1</sub> can be administered by slow IV infusion when there is a greater urgency to reverse anticoagulation. The 1998 American College of Chest Physicians recommendations for managing patients receiving coumarin anticoagulants who need their INRs lowered because of actual or potential bleeding are listed at the end of this chapter. These recommendations have not changed in the last 2 years and are all grade 2C.

#### MANAGEMENT OF ORAL ANTICOAGULATION DURING INVASIVE PROCEDURES

Clinicians often are required to assess the risk of bleeding from a procedure if anticoagulation therapy is continued vs the risk of thrombosis if anticoagulation therapy is discontinued, as well as the cost of alternative anticoagulation options. This subject has been reviewed with suggested alternative options based on an estimate of the preoperative and postoperative daily risk of bleeding or thrombosis.<sup>40</sup> With each of the following options, the length of time for warfarin dosage reduction and for the duration of heparin or low-molecular-weight heparin (LMWH) use preoperatively can be shortened by administering vitamin K<sub>1</sub> 24 to 48 h before surgery to reverse the warfarin effect. Traditionally, full dose, IV, unfractionated heparin has been the standard therapy for patients who need full anticoagulant protection that is readily reversible before a procedure. Its major drawback is the complexity and cost associated with IV heparin therapy and hospitalization. LMWH now offers another, simpler alternative approach. Johnson and Turpie<sup>41</sup> used LMWH in a prospective cohort study (dalteparin, 100 anti-Xa U/kg, subcutaneous [SC], bid) in 112 patients with mechanical heart valves, atrial fibrillation, or venous thromboembolism undergoing urologic, cardiac, eye, or dental procedures. Patients received an average of five doses before the procedure and 4.3 doses started 8 to 12 h after the procedure. Patients discontinued warfarin therapy for an average of 5.4 days. One patient experienced a major episode of bleeding in the rectus muscle at the injection site. There were no thromboembolic events. Tinmouth et al<sup>42</sup> reported on a prospective cohort of 27 patients with mechanical heart valves, atrial fibrillation, and venous thromboembolism who were at high risk for stroke. Patients received LMWH (dalteparin, 200 anti-Xa U/kg SC qd) on the 2 days before the procedure, and therapy was restarted 12 to 24 h after the procedure. Warfarin therapy was discontinued 4 days before the procedure. Among the

22 evaluable patients, there were two episodes of minor bleeding, and one patient experienced a transient ischemic attack. The investigators also demonstrated a \$4,285 (Canadian) per patient savings as a result of using LMWH as an outpatient to avoid hospitalization. Last, Spandorfer et al<sup>43</sup> treated a cohort of 20 patients who had prosthetic cardiac valves, atrial fibrillation, or thrombophilia with LMWH (enoxaparin, 1 mg/kg SC bid) in preparation for a variety of invasive procedures. Warfarin therapy was stopped 5 to 6 days before the procedure, and LMWH therapy was started 36 h later and then stopped 12 to 18 h before the procedure. LMWH therapy was restarted at a mean of 13.5 h after the procedure. One patient experienced a significant drop in hemoglobin of 2 g/dL after the procedure. No thromboembolic complications developed. The results of these three studies suggest that LMWH is a simple and less costly alternative for full anticoagulation protection, but randomized, controlled trials are still needed to identify the best means of alternative anticoagulation therapy. Recommendations for the management of anticoagulation therapy during invasive procedures are presented at the end of this article.

Dental procedures represent a particularly common intervention for patients receiving anticoagulant therapy. A comprehensive review of the subject<sup>44</sup> indicated that in most cases, no change in the intensity of anticoagulation is needed. To our knowledge, there are no well-documented cases in the literature of serious bleeding in this setting, but there are a number of documented cases of embolic events in patients whose warfarin therapy was discontinued for dental treatment. If there is a need to control local bleeding, tranexamic acid or epsilon amino caproic acid mouthwash has been used successfully without interrupting anticoagulant therapy.<sup>45,46</sup>

## ADVERSE EVENTS (HEMORRHAGE)

### *Definition of Major and Minor Hemorrhage*

Precise estimates of hemorrhagic event rates are complicated by the inconsistency between classification schemes in clinical research studies.<sup>12</sup> The goal of classification is to place a bleeding episode on a continuum of severity ranging from minor events, such as brief epistaxis that would not have been reported to a physician (but would, for example, be recorded as part of a clinical trial), to a fatal or life-threatening episode of bleeding. Fihn et al<sup>12</sup> established the following three categories: minor (reported, but not requiring additional testing, referrals, or visits); major (requiring treatment, medical evaluation, or at least 2 U blood); and life threatening (leading to cardiac arrest, surgical/angiographic intervention, or irreversible sequelae). Most other investigators, however, divide adverse events into minor and major categories, with major events including fatal or life-threatening bleeding episodes (eg, intracranial or retroperitoneal) or bleeding with a defined drop in hemoglobin level, leading to transfusion of a specified number of units of blood or to hospitalization. The reader must be aware of these discrepancies when interpreting the results from clinical studies. For purposes of comparison between studies, we suggest that investiga-

tors define hemorrhagic events into major and minor categories with qualifying criteria such as those examples listed above.

### *Risk Factors for Adverse Events*

**Intensity of Treatment:** Bleeding is the main complication of oral anticoagulant therapy. The most important factor influencing the risk of bleeding is the intensity of anticoagulant therapy.<sup>4-14</sup> Four randomized studies have specifically demonstrated that the risk of clinically important bleeding is reduced by lowering the therapeutic range from 3.0 to 4.5 to 2.0 to 3.0.<sup>4-7</sup> A number of additional studies have shown what amounts to an exponential increase in hemorrhagic events as the INR increases > 5.0.<sup>8,10,11,47</sup>

**Patient Characteristics:** Several patient characteristics have been shown to be associated with higher odds of bleeding during anticoagulation therapy.<sup>8,12-14,47-56</sup> The patient factor most consistently demonstrated to be predictive of episodes of major bleeding is a history of bleeding (especially GI bleeding).<sup>12,13,51</sup> Other factors that have been shown to be associated include a history of stroke and the presence of a serious comorbid condition, such as renal insufficiency, anemia, or hypertension.<sup>12-14,47-56</sup> The relationship between older age and anticoagulant-associated bleeding is controversial. Several reports have suggested that older individuals are not at an increased risk for bleeding,<sup>12,48,57-67</sup> while others have described such an association.<sup>8,13,47,52,54,68-71</sup> This issue is of clinical importance since older individuals often have conditions that warrant anticoagulation therapy and some recommendations for anticoagulation have been based in part on patient age.<sup>71</sup> Establishing a causal association between old age *per se* and an increased risk of anticoagulant-associated bleeding is difficult since age may simply be associated with comorbid conditions, which themselves are risk factors for bleeding (eg, colonic polyps, concomitant medications, or poor anticoagulant control due to lack of compliance). Some studies indicate that older patients who have high-quality anticoagulation management, such as that provided by an anticoagulation clinic, have the same risk of bleeding as their younger counterparts.<sup>27</sup> Some studies that attempted to separate the effect of age from comorbid conditions associated with age concluded that age in and of itself is not a major independent risk factor,<sup>12,59,72,73</sup> while others have found it to be an independent risk factor<sup>8,14</sup> even after controlling for the intensity of the anticoagulant effect. Individuals who are otherwise good candidates for anticoagulation therapy should not have it withheld because of their age. However, elderly patients should be monitored more carefully in order to maximize their time in the therapeutic range (grade 2C, see "Recommendations" section).

**TTR:** A strong relationship between TTR and bleeding or thromboembolic rates has been observed across a large number of studies with different patient populations, different target ranges, different scales for measuring the intensity of anticoagulation (ie, PT, PT ratio, and INR),

and different models of dose management.<sup>10,11,47,57,60,74-78</sup> In a large representative study by Cannegieter et al,<sup>10</sup> the relationship between TTR and major episodes of bleeding was approximately exponential; that is, small departures from the target range were associated with small-to-moderate increases in bleeding rates, while large departures from the target range were associated with large

increases in bleeding rates. A similar relationship holds for TTR and thromboembolism rates, and when bleeding and thromboembolism are considered simultaneously, the overall relationship is U-shaped. Table 1 summarizes the data from those studies, assessing the quality of anticoagulation therapy as reflected by TTR. Most studies, however, fail to measure the quality of anticoagulation man-

**Table 1—TTR (a Surrogate Measure for Quality) Achieved Under Different Models of Anticoagulation Management and With Different Testing Frequencies\***

Study/Year	Predominant Management Model	PTR vs INR	PTR, %†	Range, %		Frequency of Monitoring	Method of Determining TTR	Major Diagnosis
				Above	Below			
Garabedian-Ruffalo et al <sup>82/1985</sup>	UC	PTR	64	—	—	—	% in range	Mixed
Gottlieb et al <sup>83/1994</sup>	UC	PTR	50	30	20	Every 25 d‡	Days in range	Mixed
Holm et al <sup>84/1999</sup>	UC	INR	63	8	29	—	% in range	Mixed
Beyth and Landefeld <sup>85/1997</sup>	UC	INR	33	16	51	—	—	Mixed
Horstkotte et al <sup>86/1996</sup>	UC	INR	59	—	—	19 d‡	% in range	Valves
Sawicki <sup>87/1999</sup>	UC	INR	34	16	50	—	% in range	AF/valves
Palaretti et al <sup>84/1996</sup>	AMS	INR	68	6	26	15 d‡	Days in range	Mixed
Cannegieter et al <sup>10/1995</sup>	AMS	INR	61	8	31	18.9 d‡	Days in range	Valves
Lundstrom and Ryden <sup>88/1989</sup>	AMS	TT	92	—	—	—	% in range	AF
Garabedian-Ruffalo et al <sup>82/1985</sup>	AMS	PTR	86	—	—	—	% in range	Mixed
White et al <sup>89/1989</sup>	AMS	PTR	75	—	—	—	Days in range	Mixed
Ansell et al <sup>90/1995</sup>	AMS	PTR	68	10	22	16 d‡	% in range	Mixed
Conte et al <sup>91/1986</sup>	AMS	PTR	59	12	29	—	—	Mixed
Seabrook et al <sup>92/1990</sup>	AMS	PTR	86	7	7	Once a month	% in range	Mixed
White et al <sup>89/1989</sup>	PST	PTR	93	—	—	—	Days in range	Mixed
Beyth and Landefeld <sup>85/1997</sup>	PST	INR	56	14	30	—	—	Mixed
Ansell et al <sup>90/1995</sup>	PSM	PTR	89	5	6	13.8 d‡	% in range	Mixed
Horstkotte et al <sup>86/1996</sup>	PSM	INR	92	—	—	4 d‡	% in range	Valves
Sawicki <sup>87/1999</sup>	PSM	INR	57	10	33	—	% in range	AF/valves
AFASAK <sup>78/1989</sup>	RCT	INR	73	0.6	26	—	—	AF
BAATAF <sup>76/1990</sup>	RCT	PTR	83	9	8	Every 3 wk	Days in range	AF
SPAF I <sup>93/1991</sup>	RCT	PTR	71	5	23	At least once a month	% in range	AF
SPAF II <sup>94/1994</sup>	RCT	PTR/INR	74	5	21	At least once a month	% in range	AF
SPAF III <sup>71/1996</sup>	RCT	INR	61	14	25	At least once a month	% in range	AF
SPINAF <sup>75/1992</sup>	RCT	PTR	56	15	29	Monthly	% in range	AF
CAFA <sup>77/1991</sup>	RCT	INR	44	16	40	Every 3 wk	Days in range	AF
AFASAK II <sup>95/1999</sup>	RCT	INR	73	9	18	Not > every 4 wk	Days in range	AF
EAF <sup>T96/1993</sup>	RCT	INR	59	9	32	Every 5 wk	% in range	AF
Hellemons et al <sup>97/1999</sup>	RCT	INR	48	24	28	Every 2-6 wk	% in range	AF
Hutten et al <sup>80/1999</sup>	RCT	INR	61	—	—	—	Days in range	DVT/PE

\*RCT = randomized controlled trial; PTR = prothrombin time ratio; TT = thrombotest; Mixed = mixed indications for anticoagulation; valves = cardiac prosthetic valve; AF = atrial fibrillation; % in range = the proportion of PT tests in range divided by the total number of tests; days in range = the estimated days or time in range as determined by various methodologies; AFASAK = Atrial Fibrillation, Aspirin, and Anticoagulant Therapy; BAATAF = Boston Area Anticoagulation Trial For Atrial Fibrillation; SPAF = Stroke Prevention in Atrial Fibrillation; CAFA = Canadian Atrial Fibrillation Anticoagulation; EAF<sup>T</sup> = European Atrial Fibrillation Trial; SPINAF = Stroke Prevention in Atrial Fibrillation Trial.

†TTR represents mean or median percentage of PTs or days in range.

‡Those studies that documented the achieved frequency of monitoring as opposed to the stated goal for monitoring interval.

agement as reflected by TTR. We believe that this is a deficiency that can lead to erroneous interpretation of results, and we urge investigators to measure TTR in their studies. There is still difficulty, however, in comparing TTR across studies because different methods are used to measure TTR. The most common method expresses the proportion of INR values within the therapeutic range as the number of INRs within the range divided by the number of PT tests. This method is biased and is likely to underestimate the TTR because the result is affected by the tendency of physicians to perform repeated tests soon after obtaining an out-of-range INR (eg, to verify the initial INR or to assess the effect of a dosage adjustment). Another approach is the *cross-section of the files* method, in which a given date is selected and the proportion of INRs within target range, using the most recent INR value, is calculated for each patient. The cross-section of the files method is unbiased but is inefficient as it fails to utilize test results between the assessment dates. Two other methods try to overcome these problems and assess actual days spent in or out of range. The *equidivision method*<sup>79</sup> assumes that the change between two consecutive INR measurements occurs halfway between the two tests. It has been shown to be reproducible but not valid.<sup>80</sup> The *linear interpolation method* of Rosendaal et al<sup>81</sup> is based on calculating the actual time in target range by first linearly interpolating between observed test values and then defining the TTR as the number of patient-days of follow-up that were within the target range divided by the total number of patient-days included in the follow-up period. The results of all of these methods depend on the choice of target INR range, and therefore, the TTR can be enhanced considerably if the target range is expanded, even in the absence of any actual improvements in the quality of anticoagulation therapy management. Another deficiency is that the various methods of assessment treat small departures from target range as identical to large departures, even though the former would have much less impact on clinical outcomes than the latter. These differences must be taken into account when comparing results across multiple studies. The data in Table 1 indicate the various methodologies used for determining TTR.<sup>10,54,71,75–78,80,82–97</sup>

*Frequency of Testing:* The optimal frequency of monitoring the INR is dependent on many factors, including patient compliance, transient fluctuations in comorbid conditions, the addition or discontinuation of treatment with other medications, changes in diet, the quality of dose-adjustment decisions, and whether treatment is early or late in the course of therapy. Some investigators have attempted to develop predictive models with the goal of reducing the frequency of testing without sacrificing quality.<sup>98</sup> The results of a few clinical trials suggest that TTR, and presumably fewer adverse events, can be maximized by more frequent testing.<sup>86,99</sup> This is particularly true in studies utilizing patient self-testing in which access to testing is virtually unlimited. Horstkotte et al<sup>99</sup> specifically addressed this issue in a study of 200 patients with mechanical cardiac valves in whom the percentage of INRs within the target range varied from 48%, when

monitoring occurred at an average interval of 24 days, to 89%, when monitoring occurred at an average interval of every 4 days. These results, however, are inconclusive because of questions about how TTR was calculated and other methodologic issues.

### *Frequency of Hemorrhage*

The frequency of hemorrhage associated with oral anticoagulant therapy is reviewed in detail in another article in this supplement (see page 108). The rate of hemorrhagic events must be interpreted not only in the context of the quality of anticoagulation management (eg, the model of anticoagulant care and TTR), but also with consideration of a number of the other factors discussed above, as well as factors such as whether therapy was monitored by the use of the PT or INR, whether the indications studied included patients with mixed diagnoses or a restricted indication, and whether the patients studied were new to anticoagulation therapy or were patients already established on a regimen of long-term therapy.

### *Nonhemorrhagic Adverse Events*

Other than hemorrhage, the most important side effect of warfarin is skin necrosis. This uncommon complication is usually observed on the third to eighth day of therapy<sup>100,101</sup> and is caused by extensive thrombosis of the venules and capillaries within the subcutaneous fat. The pathogenesis of this striking complication and the reason for the localization of the lesions are mysterious. An association between warfarin-induced skin necrosis and protein C deficiency<sup>102–104</sup> and less commonly, protein S deficiency,<sup>105</sup> has been reported, but this complication also occurs in nondeficient individuals. A pathogenic role for protein C deficiency is supported by the similarity of the lesions to those seen in neonatal purpura fulminans that complicates homozygous protein C deficiency. The management of patients with warfarin-induced skin necrosis who require life-long anticoagulant therapy is problematic. Warfarin is considered to be contraindicated, and long-term heparin therapy is inconvenient and associated with osteoporosis. A reasonable approach in such patients is to restart warfarin therapy at a low dose (eg, 2 mg), under the coverage of therapeutic doses of heparin, and to increase the warfarin dosage gradually over several weeks. This approach should avoid an abrupt fall in protein C levels before there is a reduction in the levels of factors II, IX, and X and has been shown to be free of a recurrence of skin necrosis in a number of case reports.<sup>103,104</sup>

## MANAGEMENT OF ADVERSE EVENTS

### *Management of the Patient Who Bleeds During Warfarin Therapy*

The short-term management of patients who bleed with an excessively prolonged INR has been discussed above. The long-term management of patients who bleed but who require ongoing protection against systemic embolism (eg, patients with mechanical heart valves or with

atrial fibrillation and other risk factors) is problematic. There are two general principles that should be followed: (1) to attempt to identify and reverse the cause of bleeding; and (2) to examine the possibility of lowering the intensity of the anticoagulant effect. Every effort should be made to treat the cause of bleeding (eg, the use of aggressive antiulcer therapy) if it is potentially reversible.

The risk of bleeding is strongly related to the intensity of the anticoagulant effect. Therefore, in patients who continue to bleed, every effort should be made to maintain the INR at the lower limit of the therapeutic range (ie, 2.0). Laboratory control of treatment should be optimized with frequent INR measurements and by ensuring that a sensitive thromboplastin (international sensitivity index [ISI], < 1.5) is used.<sup>106</sup> For patients with mechanical prosthetic valves (and a persisting risk of increased bleeding), it would be reasonable to aim for an INR range of 2.0 to 2.5. For patients with atrial fibrillation (and a persisting risk of increased bleeding), the anticoagulant intensity can be reduced to an INR range of 1.5 to 2.0 with the expectation that efficacy will be reduced but not abolished.<sup>9</sup> Alternatively, aspirin can be used to replace warfarin in patients with atrial fibrillation, but also with a reduced efficacy in high-risk patients.

### Diagnostic Evaluation of Bleeding

When bleeding occurs, especially from the GI tract or urinary tract, it is important to consider the possibility of a serious, underlying occult lesion as the source of bleeding. A number of descriptive studies indicate the probability of finding such a lesion.<sup>68,107,108</sup> Coon and Willis<sup>68</sup> identified occult lesions responsible for bleeding in 11% of 292 patients with hemorrhage. Jaffin et al<sup>107</sup> found a 12% prevalence of positive results in stool occult blood tests in 175 patients receiving warfarin or heparin compared with 3% in 74 control subjects. There was no difference between the mean PT or activated partial thromboplastin time in patients with positive and negative test results. In 16 patients evaluated, 15 had lesions not previously suspected and 4 had neoplastic disease. Landefeld et al<sup>14</sup> found 14 of 41 patients with GI bleeding to have important remediable lesions, of which two lesions were malignant. This limited information supports the need for investigation, since if occult blood is found in the stool, there may be a 5 to 25% chance of finding a malignant source.

In a randomized controlled study, Culclasure et al<sup>109</sup> found microscopic hematuria at a prevalence of 3.2% compared with a prevalence of 4.8% in their control group. There was no difference in the rate of hematuria with therapeutic or high INRs. Following a second episode of hematuria, 43 patients (32 receiving anticoagulation therapy and 11 control patients) were investigated; 27 of the anticoagulated patients (84%) and 8 of the control patients (73%) were found to have significant underlying disease, with three cancers found in the combined group (7%). These findings are in contrast to the results of other case series identifying a much higher likelihood of finding underlying lesions in patients who develop hematuria while receiving anticoagulant therapy.<sup>110-112</sup>

## MODELS OF ANTICOAGULATION MANAGEMENT

The effectiveness and safety of warfarin are critically dependent on maintaining the INR in the therapeutic range. This objective is facilitated by aiming for an INR that is in the middle of the INR range (ie, a goal of 2.5 for a designated range of 2.0 to 3.0, and a goal of 3.0 for a designated range of 2.5 to 3.5). The impact of maintaining good anticoagulant control was highlighted by reanalysis of the primary prevention trials in atrial fibrillation using an on-treatment analysis.<sup>1</sup> The results of the on-treatment analysis showed that a majority of the events (both thromboembolic and bleeding) occurred when the PT ratio was outside the designated therapeutic range and that both the safety and efficacy of warfarin were increased by maintaining good anticoagulant control. Subgroup analyses of other cohort studies have also shown a sharp increase in the risk of bleeding when the INR is higher than the upper limit of the therapeutic range.<sup>8,10,113,114</sup>

Approaches to improve anticoagulant control include the use of (1) anticoagulation management services (AMSs) (ie, anticoagulation clinics) to manage therapy, (2) point-of-care (POC) PT testing that allows patient self-testing (PST) and patient self-management (PSM) of dose adjustments, and (3) computer programs to aid in dose adjustment.

### Usual Care vs AMSs

There is growing evidence that better outcomes are achieved when anticoagulation is managed by an AMS compared to patients managed by their personal physicians (ie, usual care [UC]). The latter is the predominant model of therapy in North America,<sup>115</sup> whereas anticoagulation clinics have long been the model of care in the United Kingdom and the Netherlands.<sup>116</sup> Unfortunately, the available literature on the benefits of an AMS consist mostly of descriptive reports, case control studies, or nonrandomized prospective studies. Extrapolation of the rates of adverse events from many of the large randomized controlled studies to everyday practice is limited by the fact that indications studied are often restricted, patients are highly selected, and monitoring and management of anticoagulation are highly coordinated.

Tables 2 to 4 summarize the results of studies assessing the frequency of hemorrhage or thrombosis based on the model of care. These studies were selected based on the following criteria: published in 1980 or later (excluding abstracts); providing sufficient information to classify the model of care as either UC or an AMS; defining the criteria for major hemorrhage; identifying the rate of major hemorrhage; and providing information to determine the number of patient-years of therapy for comparative purposes. Table 2 summarizes three large retrospective observational studies on UC.<sup>13,51,55</sup> Each study reports on patients followed up by private physicians in a particular locale. Results indicate a frequency of major hemorrhage of approximately 7.7% per patient-year of therapy, with recurrent thromboembolism of 8.1% per patient-year in one study. Table 3 summarizes the results achieved with an AMS from mostly retrospective observational analyses that met selection criteria.<sup>10,12,47,54,57-61,91,92,117</sup> A majority

**Table 2—Frequency of Major Hemorrhage/Thromboembolism in Patients Managed Under a UC Model of Management\***

Study/Year	Patients, No.	Patient-yr, No.	Data Collection, yr	New or Established Patients	Indications	Hemorrhage		Recent TE†	Definition of Major Bleeding
						Major†	Fatal†		
Landefeld and Goldman <sup>13</sup> /1989	565	876	1977–1983	New	Ven art	7.4	1.1	NA	Fatal or life-threatening (surgery, angiography, irreversible damage); potentially life-threatening ( $\geq 3$ U blood, hypotension, hct $\leq 20$ )
Gitter et al <sup>55</sup> /1995	261	221	1987–1989	Established	Ven art	8.1	0.45	8.1	$\geq 2$ U blood in $\leq 7$ d; life-threatening bleeding
Beyth et al <sup>51</sup> /1998	264	440	1986–1993	New	Ven art	5.0	0.68	NA	Overt bleeding that led to loss of $\geq 2$ U in $\leq 7$ d or life-threatening bleeding

\*Ven art = mixed indications in the venous and arterial system; NA = not available; hct = hemoglobin count; TE = thromboembolism.

†Values expressed as percent per patient-year of therapy; fatal hemorrhagic events also included with major hemorrhage.

of the earlier studies used a PT ratio to monitor therapy, thereby potentially providing more intense therapy. Higher rates of bleeding are noted in these earlier studies compared to the last three that employed an INR to monitor therapy. Table 4 summarizes the four studies in which investigators used clinical outcomes to compare two models of care in a single setting.<sup>53,82,118,119</sup> All of these studies used a before-and-after design, and none were prospective randomized trials. In two studies,<sup>53,82</sup> the same patient groups were observed first in a UC setting and then in an AMS setting. The third study<sup>118</sup> involved two defined cohorts of patients, and the fourth report<sup>119</sup> provided data on the following three sequential inception cohorts: an initial AMS; then a UC cohort; followed by a second AMS cohort. Although none of these trials were randomized, each reported an impressive reduction in the incidence of major hemorrhage and thromboembolism, and the one study that evaluated death due to bleeding or thromboembolism found a reduction that approached statistical significance ( $p = 0.09$ ).<sup>119</sup>

Although these results suggest that the coordinated approach of an anticoagulation clinic is superior to UC, the studies were not randomized and therefore, they need to be validated. A recently completed prospective randomized trial (the MAST trial)<sup>120</sup> should provide more definitive information in this regard as preliminary evidence suggests.<sup>18</sup>

### Cost-effectiveness of UC vs AMS

Because of improved outcomes with fewer hospitalizations and emergency department visits, the management of anticoagulation therapy by an AMS may prove to be cost effective. Gray et al<sup>121</sup> estimated a savings of \$860 per patient-year of therapy in 1986 due to reduced hospital days in a study of patients treated by an AMS vs UC. Chiquette et al<sup>119</sup> found a savings of \$1,621 per patient-year of therapy in their comparative study due to a significant reduction in hospitalizations and emergency department visits. Last, Wilt et al<sup>118</sup> found an extremely high rate of savings (\$4,072 per patient-year of therapy)

due to reduced utilization of services. These observations need to be validated by randomized studies.

### POC PST and PSM

Recent technological advances in POC PT measurement offer the potential for both simplifying and improving oral anticoagulation management in the professional setting as well as at home. POC monitors measure a thromboplastin-mediated clotting time that is then converted to a plasma PT equivalent by a microprocessor and expressed as a PT or INR. Three monitors are approved for PST at home<sup>122</sup> (Table 5).

The validity of this methodology was initially established in 1987 by Lucas et al<sup>123</sup> using a monitoring instrument (Coumatrak; Biotrack Inc; Fremont, CA) that showed an  $r$  value of 0.96 between reference plasma PTs and capillary whole-blood PTs in 858 samples from 732 subjects (*ie*, control subjects, warfarin-treated patients, and heparin-treated patients). Within-day precision using two different levels of control subjects revealed coefficients of variation (CVs) of 4.9% and 2.9%. The accuracy of the instrument was not compromised by hematocrit measurements ranging from 23 to 54%. Other studies have confirmed the accuracy of the instrument ( $r = 0.95$ )<sup>124</sup> compared to reference laboratory methods ( $r = 0.91$ ).<sup>125</sup>

POC instruments, however, do have limitations, as demonstrated by other studies. Using a derivative of the Biotrack ProTime monitor (Biotrack 512; Ciba Corning; Medfield, MA), Jennings et al<sup>126</sup> found poor comparability between the instrument and the thrombotest, with the former underestimating the INR by a mean of 0.76 INR units. The precision of the instrument was considered to be good (CV, 7.5% and 4.5%, respectively). McCurdy and White,<sup>127</sup> with another derivative of the Biotrack monitor (Coumatrak; DuPont; Wilmington, DE), found that the capillary method yielded the most accurate results in an INR range of 2.0 to 3.0, but that the results of the two methods became discrepant as the INR increased. Tripodi et al<sup>128</sup> found with the Biotrack 512 model that by recalibrating the ISI of the instrument's thromboplastin



**Table 3—Frequency of Major Hemorrhage/Thromboembolism in Patients Managed Under an AMS\***

Study/Year	Patients, No.	Patient-yr, No.	Data Collection, yr	New or Established Patients	Indications	Target		Hemorrhage†		Recent TE†	Definition of Major Bleeding
						PTR	INR	Major	Fatal		
Forfar <sup>57</sup> /1982	541	1,362	1970–1978	Both	Ven art	1.8–2.6		4.2	0.14	NA	Significant bleeding requiring medical advice (exclude bruises and epistaxis)
Errichetti et al <sup>58</sup> /1984	141	105	1978–1983	Both	Ven art	1.3–2.0		6.6	NA	NA	Bleeding leading to hospitalization, transfusion, or discontinuing therapy
Conte et al <sup>91</sup> /1986	140	153	1975–1984	Both	Ven art	1.7–2.5		2.6	NA	8.4	Bleeding leading to hospitalization, discontinuing, or reversal of therapy
Petty et al <sup>59</sup> /1988	310	385	1977–1980	Both	Ven art		NA	7.3	0.77	NA	Life-threatening bleeding (GI, intracranial, subdural, or death); discontinuing therapy
Charney et al <sup>60</sup> /1988	73	77	1981–1984	Both	Ven art	1.5–2.5		0	0	5.0	Bleeding leading to hospitalization or discontinuing therapy
Bussey et al <sup>61</sup> /1989	82	199	1977–1986	New	Ven art	NA		2.0	NA	3.5	Bleeding leading to hospitalization, transfusion, vitamin K, or fresh frozen plasma
Seabrook et al <sup>92</sup> /1990	93	158	1981–1988	New	Ven art	1.5–2.0		3.8	0	2.5	Bleeding leading to hospitalization, transfusion, or discontinuing therapy
Fihn et al <sup>12</sup> /1993	928	1,950	NA	New	Ven art	1.3–1.5		1.7	0.2	7.5	Fatal or life-threatening bleeding (CPR, 1.5–1.8 surgery angiography, irreversible damage, hypotension, hct < 20, ≥ 3 U blood)
van der Meer et al <sup>47</sup> /1993	6,814	6,085	1988	Both	Ven art		2.4–5.3	3.3	0.64	NA	Fatal bleeding; intracranial bleeding, transfusion, or surgery; all muscle and joint bleeding
Cannegieter et al <sup>10</sup> /1995	1,608	6,475	1985 to present	Both	Mech valves		3.6–4.8	2.5	0.33	0.7	Fatal or bleeding leading to hospitalization
Palareti et al <sup>54,117</sup> /1996, 1997	2,745	2,011	1993–1995	New	Ven art‡		2.0–3.0	1.4	0.24	3.5	Fatal bleeding; intracranial bleeding, ocular bleeding with blindness; joint, retroperitoneal bleeding; surgery or angiography, > 2 g blood; transfusion ≥ 2 U

\*Mech valves = mechanical cardiac prosthetic valve. See Tables 1 and 2 for abbreviations not used in text.

†Values expressed as percentage per patient-year of therapy; fatal hemorrhagic events also included with major hemorrhage.

‡INR, 2.5 to 4.5.

against the secondary international reference preparation (IRP) for rabbit thromboplastin, it was systematically higher (ISI, 2.715) than that reported by the manufacturer (ISI, 2.036). Like McCurdy and White,<sup>127</sup> they found that the monitor underestimated the results as the INR increased (*ie*, INR > 4.0). However, this error was not instrument-related but the result of a faulty ISI; the error did not occur when the INR was recalculated using their recalibrated ISI.

In a second class of PT monitors (CoaguChek; Roche Diagnostics; Indianapolis, IN), Oberhardt et al<sup>129</sup> reported an *r* value of 0.96 in 271 samples compared to standard laboratory methods. Rose et al<sup>130</sup> determined within-day precision for normal and abnormal control plasmas with CVs of 3.7% and 3.6%, respectively. An *r* value of 0.86 was obtained from 50 outpatients compared with reference plasma PTs. Fabbri et al<sup>131</sup> also found reasonable precision (CV, 6% and 4%) with excellent correlation coeffi-

**Table 4—Frequency of Major Hemorrhage/Thromboembolism in Patients Managed Under UC vs AMS\***

Study/Year	Model of Care	Patients, No.	Patient-yr, No.	Data Collection, yr	Indications	Target		Hemorrhage†		Recent TE‡	Comb Hemorrhage/TE‡	Cost Savings†
						PTR	INR	Major	Fatal			
Garabedian-Ruffalo et al <sup>82</sup> /1985	UC	26	64.3	1977–1980	Ven art‡	1.5–2.5		12.4	0	6.2	18.6	
	AMS	26	41.9	1980–1983	Ven art	1.5–2.5		2.4	0	0	2.4	\$ 860
Cortelazzo et al <sup>53</sup> /1993	UC	271	677	1982–present	Mech valves	25–35%‡		4.7	0	6.6	11.3	
	AMS	271	669	1987–1990	Mech valves		3.0–4.5	1.0	0	0.6	1.6	
Wilt et al <sup>118</sup> /1995	UC	44	28	1988–1993	Ven art		NA	17.8	0	42.8	60.6	
	AMS	68	60	1988–1993	Ven art		NA	0	0	0	0	\$4,072
Chiquette et al <sup>119</sup> /1998	AMS	82	199	1977–1986	Ven art		NA	2.0	NA	3.5	5.5	
	UC	142	102	1991–1992	Ven art		NA	3.9	0.9	11.8§	15.7	
	AMS	176	123	1992–1994	Ven art		NA	1.6	0	3.3	4.9	\$1,621

\*See Tables 1, 2, and 3 for abbreviations not used in text.

†Values expressed as percentage per patient-year of therapy; fatal hemorrhagic events included with major hemorrhage.

‡Prothrombin activity.

§2 TE events fatal.

patients ( $r = 0.92$  and  $0.91$ ) compared with reference plasma PTs in two different groups of patients.

Tripodi et al<sup>132</sup> evaluated the calibration of the ISI in the CoaguChek system based on an IRP and found that they were extremely close to those adopted by the manufacturer for both whole blood and plasma. Although the CVs of the slopes of the regression lines comparing the system with an international reference were excellent (*ie*, a CV of 2.2 for both whole blood and plasma on the instrument compared with the international reference), the instrument reported significantly higher INRs (whole blood INR, 3.20; plasma INR, 3.41; reference system

INR, 2.92) using the manufacturer's calibration. The differences were due to a lower mean normal PT adopted by the manufacturer.

Kaatz et al<sup>133</sup> evaluated both classes of monitors (CoaguChek and Biotrack) as well as four clinical laboratories against the criterion standard established by the World Health Organization (WHO) using an international reference thromboplastin level and the manual tilt-tube technique. They found that laboratories using a more sensitive thromboplastin showed close agreement with the criterion standard, whereas laboratories using an insensitive thromboplastin showed poor agreement. The two monitors fell

**Table 5—Capillary Whole-Blood (POC) PT Instruments\***

Instrument	Clot Detection Methodology	Home Use Approval	Type of Sample
Biotrack ProTIME Monitor 1000 Coumatrak† Biotrack 512 coagulation monitor† CoaguChek Plus† CoaguChek Pro† CoaguChek Pro/DM†	Clot initiation: thromboplastin Clot detection: cessation of blood flow through capillary channel		Capillary WB and venous WB
CoaguChek thrombolytic assessment system	Clot initiation: thromboplastin Clot detection: cessation of movement of iron particles	Yes (CoaguCheck only)	Capillary WB, venous WB, and plasma
ProTIME Monitor Hemochron Jr‡ GEM PCL‡	Clot initiation: thromboplastin Clot detection: cessation of blood flow through capillary channel	Yes	Capillary WB and venous WB
Avocet PT 1000	Clot initiation: thromboplastin Clot detection: thrombin generation detected by fluorescent thrombin probe	Yes	Capillary WB, venous WB, and plasma

\*WB = whole blood.

†Instrument based on the original Biotrack ProTIME Monitor 1000 and licensed under different names. The latest version available is the CoaguChek Pro and Pro/DM (as models evolved they acquired added capabilities). Earlier models are no longer available.

‡Simplified versions of the ProTIME Monitor. Hemochron Jr is manufactured by International Technidyne. GEM PCL is manufactured by Instrumentation Laboratory, Lexington, MA.

between these two extremes. As in the study by McCurdy and White,<sup>127</sup> the Coumatrak underestimated the INR at values > 2.5, whereas the CoaguChek simply showed more scatter at INR values > 2.75. INR determinations of the Coumatrak monitor and the CoaguChek were only slightly less accurate than those of the best clinical laboratories.

A third class of POC capillary whole-blood PT instrumentation (ProTIME Monitor; International Technidyne Corporation; Edison, NJ) differs from the previously described instruments in that this instrument performs a PT in triplicate (*ie*, three capillary channels) and simultaneously performs a level 1 and level 2 control (*ie*, two additional capillary channels). In a multi-institutional trial,<sup>134</sup> the instrument INR correlated well with the reference laboratory with tests performed by either the health-care provider (venous sample,  $r = 0.93$ ) or the patient (capillary sample,  $r = 0.93$ ). PT results for fingersticks performed by both the patient and the health-care provider were equivalent and correlated highly ( $r = 0.91$ ).

In a separate report involving 76 warfarin-treated children and 9 healthy control subjects, Andrew et al<sup>135</sup> found a correlation ( $r = 0.89$ ) between venous and capillary samples. Both results, compared with venous blood tested in a reference laboratory (ISI, 1.0), revealed correlation coefficients of 0.90 and 0.92, respectively.

A fourth type of PT monitor (Avocet PT 1000; Avocet Medical; San Jose, CA) has been studied in 160 subjects and was found to yield good correlation with a reference laboratory INR when compared to capillary blood ( $r = 0.97$ ), citrated venous whole blood ( $r = 0.97$ ), and citrated venous plasma ( $r = 0.96$ ).<sup>136</sup> Within-day precision was acceptable (citrated whole blood CV, 4.8% and citrated plasma CV, 5.5%, respectively).

Despite the studies noted above, steps are still needed to ensure conformity of POC PT monitors to the WHO INR PT standardization scheme. The WHO ISI calibration procedure is not practicable on the monitors. It demands parallel testing using a conventional PT test and the manual technique with a thromboplastin IRP using citrated blood samples taken at the same time or from the same blood specimen as the uncitrated whole blood tested with the monitor. Specimens from 60 warfarin-treated patients and 20 healthy subjects are required for the ISI calibration. The recently revised WHO guidelines<sup>137</sup> further specify that the calibration be performed by the manufacturer at more than one center. A simpler procedure for ISI calibration of POC monitors is needed and a method based on the use of certified lyophilized plasma calibrants is being evaluated in a current European Concerted Action on Anticoagulation multicenter study.

## PST

Self-testing and/or self-management by the patient using POC instruments represents another model of care with the potential for improved outcomes as well as greater convenience.<sup>138</sup> Self-testing provides a convenient opportunity for increased frequency of testing when deemed necessary. The use of the same instrument provides a degree of consistency in instrumentation, and

self-testing provides the potential for greater knowledge and awareness of therapy leading to improved compliance.

White et al,<sup>89</sup> in a small randomized controlled study, assessed patients' abilities to measure their own PT following hospital discharge with warfarin dosing managed by their health-care providers. These self-testing patients ( $n = 23$ ), when compared with a control group treated by an AMS ( $n = 23$ ), spent a greater percentage of the TTR (87% vs 68%, respectively;  $p < 0.001$ ) and were significantly less likely to be in the subtherapeutic range during the follow-up period (6.3% vs 23%, respectively;  $p < 0.001$ ). This study was underpowered to detect differences in outcomes of hemorrhage or thrombosis.

Anderson et al<sup>139</sup> confirmed the feasibility and assessed the accuracy of PST at home in a prospective cohort of 40 individuals who monitored their own therapy over a period of 6 to 24 months. Based on either a narrow or expanded therapeutic range, they observed a mean level of agreement per patient with reference plasma PTs of 83% by narrow criteria and 96% by expanded criteria. Ninety-seven percent of the patients preferred home testing to standard management. Andrew et al<sup>140</sup> similarly evaluated the use of a home PT monitor (ProTIME; International Technidyne; Edison, NJ) in 82 adults and 11 children. No difference was detected between INR results obtained from the home PT monitors and the laboratory, and the results were highly correlated ( $r = 0.92$ ). Ninety-five percent of participants preferred using the PT monitor over the usual laboratory testing.

Beyth and Landefeld<sup>85</sup> randomized 325 newly treated elderly patients, 163 of whom had their doses managed by a single investigator based on INR results from PST at home compared with 162 treated by their private physicians (UC) based on venous sampling. Over a 6-month period, the investigators recorded a rate of major hemorrhage of 12% in the latter group vs 5.7% in the self-testing group. This finding was based on an intention-to-treat analysis. For those patients actually performing self-testing, there was only a 1.2% incidence of major hemorrhage.

## PSM

In 1974, Erdman et al<sup>141</sup> first tested the concept of PSM of oral anticoagulation based on physician-derived guidelines with PTs obtained on plasma samples by routine laboratory instrumentation. In nearly 200 patients with prosthetic heart valves who were managing their own therapy, they found a greater degree of satisfactory anticoagulation (98% of 195 patients enrolled) compared with a retrospective survey of standard management patients who achieved only a 71% degree of adequate anticoagulation.

Ansell et al<sup>90,142</sup> analyzed the results of PSM with the Biotrack instrument over a span of 7 years in a cohort of 20 patients ranging in age from 3 to 87 years with diverse indications for anticoagulation. Compared with an age-matched, sex-matched, and diagnosis-matched control group treated by an AMS, self-managed patients were found to be in the therapeutic range for 88.6% of the PT determinations compared with 68% for the control subjects ( $p < 0.001$ ). There were also fewer dose changes for

study patients (10.7%) than for control subjects (28.2%;  $p < 0.001$ ), while complication rates did not differ between the groups. Patient satisfaction was extremely high with this mode of therapy, based on a patient survey of attitudes.

In a retrospective analysis, Bernardo<sup>143</sup> reported on 216 patients who managed their own therapy between 1986 and 1992 and found that 83.1% of the PT results were within target therapeutic range and that no serious adverse events had occurred. Horstkotte et al<sup>86</sup> performed a randomized controlled study of 150 patients with prosthetic heart valves who managed their own therapy ( $n = 75$ ) compared with a control group ( $n = 75$ ) who were managed by their private physicians (UC). The patients who self-managed tested themselves approximately every 4 days and achieved a 92% degree of satisfactory anticoagulation as determined by the INR. The physician-managed patients were tested approximately every 19 days and only 59% of INRs were in therapeutic range. The self-managed individuals experienced a 4.5% per year incidence of any type of bleeding and a 0.9% per year rate of thromboembolism compared with 10.9% and 3.6% rates, respectively, among patients in the physician-managed group ( $p = 0.038$  between the two groups). Hasenkam et al<sup>144</sup> confirmed the effectiveness of self-management in 20 patients with prosthetic valves, reporting that these patients were in the therapeutic range 77% of the time compared to 53% of the time for 20 retrospectively matched control patients. Sawicki<sup>87</sup> randomized 90 patients to self-management compared to 89 managed by their personal physician (UC). INRs were examined after 3 months, and the PSM patients were significantly closer to their target INR and had a greater percentage of values within the therapeutic range compared to the UC group. These differences were not significant (NS) at 6 months.

Finally, a large randomized controlled German study (Early Self-Controlled Anticoagulation Study)<sup>145</sup> reported preliminary results from 50% of the target patient enrollment. Three hundred five patients using PSM achieved a greater frequency of INRs in range (78.3%) than did 295 UC patients (60.5%). There was a significant difference in major adverse events between groups as well (UC group, 15%; PSM group, 9.5%;  $p = 0.03$ ).

Although a growing number of studies indicate the superiority of patient PST or PSM over UC, there is little evidence comparing them to care provided by an AMS. PST and PSM require special patient training to implement, and therapy should be managed by a knowledgeable provider. A definitive recommendation cannot yet be made as to the overall value of PST or PSM.

### Data Management and Computerized Dosing

An obstacle to the safety and effectiveness of warfarin therapy is the poor quality of dose management as currently practiced.<sup>17</sup> Data from clinical trials on success in achieving TTR are difficult to evaluate because of problems of how TTR is determined and whether narrow or expanded ranges are considered, as noted above. Corre-

lating such results with adverse event rates is also complicated by the fact that the older literature based results on a PT ratio, whereas therapy based on an INR with low and high intensity levels of treatment is a relatively recent phenomenon. Nevertheless, where data are available (Table 1), results indicate a wide range of success in achieving TTR. A UC model appears to yield the worst results with a TTR between 33% and 64%. Even in randomized controlled trials in which patient care is often highly structured, TTR varies between 48% and 83%. Achieved TTR appears to be the best in either an AMS model or with PSM (*ie*, approximately 60 to 90%). Computer assistance by the use of dedicated programs may, however, improve dose management and TTR. Although programs differ, they typically calculate whether dose adjustment is necessary from a user-defined table of trend rules for each therapeutic range. If it recommends dose adjustment, the current INR is compared to the target INR and the difference in INR is used in a proprietary equation to calculate the new dose. The time to the next dose is also set by the program using a set of variables comparing the current INR, the interval from the last test, the number of previous changes, and the number of previous INR values within the target range.

A number of older studies have evaluated computer programs to improve warfarin dosing.<sup>146–148</sup> The first randomized study in 1993<sup>149</sup> showed that three contemporary computer programs all performed as well as an experienced medical staff of an AMS in achieving a target INR of 2.0 to 3.0, but the computer achieved significantly better control when more intensive therapy was required (INR, 3.0 to 4.5). In another randomized study<sup>150</sup> of 101 long-term anticoagulated patients with prosthetic cardiac valves, computerized adjustments in warfarin dosage proved comparable to manual regulation in the percentage of INR values maintained within the therapeutic range, but they required 50% fewer dose adjustments. The first multicenter randomized trial of one computerized dosage program in 1998<sup>151</sup> showed a 22% overall improvement of control with the program (Dawn AC; 4S Information Systems, Cumbria, United Kingdom) compared to performance by the medical staff. The computer program gave significantly better INR control than experienced medical staff for all 285 patients for all target INR ranges. The study also showed that the natural increased caution of medical staff in dosing patients at a higher INR range is not shared by the computer. It cannot be assumed, however, that all computer programs will be equally successful, and new programs will require independent validation by randomized controlled studies to determine the extent of their ability to accurately predict dosage control.

### SPECIAL SITUATIONS

#### Pregnancy

Oral anticoagulants cross the placenta and can produce a characteristic embryopathy, CNS abnormalities, fetal bleeding, or increased rates of fetal death.<sup>152,153</sup> These

complications are discussed in detail elsewhere in this supplement (see page 122). The incidence of warfarin embryopathy is greatest during 6 to 12 weeks' gestation, and warfarin should be avoided during this period of pregnancy.<sup>152</sup> Since CNS abnormalities, fetal bleeding, and fetal death may occur throughout pregnancy, oral anticoagulants, if possible, should be avoided throughout the entire pregnancy. Recent evidence suggests that the risk of adverse fetal outcomes relates in part to the maternal daily dose of oral anticoagulants. Vitale and colleagues<sup>153</sup> reported for sodium warfarin that the incidence of spontaneous abortions and fetal abnormalities significantly increased if the daily dose exceeded 5 mg. The one potential indication for warfarin use during pregnancy is for patients with mechanical heart valves who have a high risk of embolism.<sup>154</sup> Uncontrolled studies have suggested that heparin may be less effective than warfarin for prophylaxis in this setting.<sup>155</sup> For other indications, heparin or LMWH is preferred when anticoagulants are indicated in pregnancy.<sup>156,157</sup> There is convincing evidence that warfarin does not induce an anticoagulant effect in the breast-fed infant when the drug is administered to a nursing mother.<sup>158</sup>

### *Antiphospholipid Syndrome*

Lupus anticoagulants are known to be associated with an increased risk of thrombosis. Consequently, it is not uncommon for patients receiving lupus anticoagulants to be placed on a regimen of oral anticoagulant therapy. Evidence from observational studies suggests that clinical outcomes are improved when the therapeutic range for patients receiving lupus anticoagulants is closer to 2.5 to 3.5 rather than 2.0 to 3.0.<sup>159,160</sup> The reasons why a higher INR may be beneficial are not known. One potential explanation is that the requirement for a higher INR is due to lupus anticoagulants interfering with the PT. Lupus anticoagulants typically cause prolongation of the activated partial thromboplastin time, but they may also cause mild prolongation of the PT or, in the presence of specific antibodies to prothrombin, significant prolongation of the PT. The degree of prolongation of the PT induced by lupus anticoagulants appears to be dependent on the reagent used.<sup>161,162</sup> One study found that INR values from patients with lupus anticoagulants receiving oral anticoagulants differed from 0.4 to 6.5 between reagents.<sup>161</sup> However, two studies have demonstrated standardization of INR values using either calibrated reference plasmas or locally assigned analyzer-specific ISI values can significantly reduce this variability.<sup>163,164</sup> These latter techniques appear to enable oral anticoagulants to be reliably monitored using the INR system for some, but not all, reagents. Other techniques for monitoring oral anticoagulant therapy for patients receiving lupus anticoagulants include the measurement of prothrombin activity, native prothrombin concentration, and the prothrombin and proconvertin test.<sup>161,165-168</sup> The validity and reliability of these latter tests have not been rigorously evaluated in controlled clinical trials for patients with lupus anticoagulants.

## RECOMMENDATIONS

### *Practical Dosing*

1. For the initiation of and maintenance dosing of warfarin, commence therapy with an average maintenance dose of 5 mg (grade 2A compared to a dose of 10 mg). Starting doses of < 5 mg might be appropriate for elderly patients, patients with impaired nutrition or liver disease, and in patients with a high risk for bleeding.

### *Management of Nontherapeutic INRs*

1. For patients with INRs greater than the therapeutic level but < 5.0 who do not have significant bleeding, lower the dose or omit a dose and resume therapy at a lower dose when the INR is at the therapeutic level. If the INR is only minimally greater than the therapeutic range, no dose reduction may be required (grade 2C).
2. For patients with INRs > 5.0 but < 9.0 with no significant bleeding, omit the next one or two doses, monitor the INR more frequently, and resume therapy at a lower dose when the INR is at the therapeutic level. Alternatively, omit the dose and administer vitamin K<sub>1</sub>, 1 to 2.5 mg orally, particularly if the patient is at increased risk of bleeding. If more rapid reversal is required because the patient requires urgent surgery, administer vitamin K<sub>1</sub>, 2 to 4 mg orally, with the expectation that a reduction of the INR will occur in 24 h. If the INR is still high, administer an additional dose of vitamin K<sub>1</sub>, 1 to 2 mg orally (all grade 2C compared with no treatment).
3. For patients with INRs > 9.0 with no significant bleeding, hold off on warfarin therapy and administer a higher dose of vitamin K<sub>1</sub>, 3 to 5 mg orally, with the expectation that the INR will be reduced substantially in 24 to 48 h. Monitor the INR more frequently and administer additional vitamin K<sub>1</sub> if necessary. Resume therapy at a lower dose when the INR reaches the therapeutic level (all grade 2C compared with no treatment).
4. For patients with INRs > 20 with serious bleeding, hold off on warfarin therapy and administer vitamin K<sub>1</sub>, 10 mg by slow IV infusion, supplemented with fresh plasma or prothrombin complex concentrate, depending on the urgency of the situation. Administration of vitamin K<sub>1</sub> can be repeated every 12 h (grade 2C).
5. For patients with life-threatening bleeding, hold off on warfarin therapy and administer prothrombin complex concentrate supplemented with vitamin K<sub>1</sub>, 10 mg by slow IV

infusion. Repeat this treatment as necessary, depending on the INR (grade 2C).

These recommendations remain unchanged from the 1998 ACCP recommendations. If the continuation of warfarin therapy is indicated after the administration of high doses of vitamin K<sub>1</sub>, then heparin can be given until the effects of vitamin K<sub>1</sub> have been reversed and the patient becomes responsive to warfarin.

### *Management of Oral Anticoagulation During Invasive Procedures*

1. For patients with low risk of thromboembolism (*eg*, patients without venous thromboembolism for > 3 months or patients who have experienced atrial fibrillation who do not have a history of stroke), stop warfarin therapy approximately 4 days before surgery, allow the INR to return to a near-normal level, briefly administer postoperative prophylaxis (if the intervention itself creates a higher risk of thrombosis) using low-dose heparin, 5,000 U SC, and simultaneously begin warfarin therapy (grade 2C).
2. For patients with intermediate risk of thromboembolism, stop warfarin therapy approximately 4 days before surgery, allow the INR to fall, cover the patient with low-dose heparin, 5,000 U SC, beginning 2 days before surgery or with a prophylactic dose of LMWH, and then commence low-dose heparin (or LMWH) and warfarin therapy after surgery (grade 2C).
3. For patients with high risk of thromboembolism (*eg*, patients with a recent [ $< 3$  months] history of venous thromboembolism, patients with a mechanical cardiac valve in the mitral position; or an old model of cardiac valve [ball/cage]), stop warfarin therapy approximately 4 days before surgery, allow the INR to return to a normal level, begin therapy with full-dose heparin or full-dose LMWH as the INR falls (approximately 2 days before surgery). Heparin can be administered as an SC injection on an outpatient basis, can then be given as a continuous IV infusion after hospital admission in preparation for surgery, and can be discontinued 5 h before surgery with the expectation that the anticoagulant effect will have worn off at the time of surgery. It is also possible to continue the administration of SC heparin or LMWH and to stop therapy 12 to 24 h before surgery with the expectation that the anticoagulant effect will be very low or will have worn off by the time of surgery (all grade 2C).
4. For patients with low risk of bleeding, continue warfarin therapy at a lower dose and operate at an INR of 1.3 to 1.5, an intensity that has been shown to be safe in randomized trials of gynecologic and orthopedic surgical patients. The

dose of warfarin can be lowered 4 or 5 days before surgery. Warfarin therapy then can be restarted after surgery and supplemented with low-dose heparin, 5,000 U SC, if necessary (grade 2C).

5. For patients undergoing dental procedures who are not considered to be at high risk for bleeding, we recommend that warfarin therapy not be discontinued. In patients at high risk for bleeding, we recommend that warfarin therapy be discontinued (all grade 2C).
6. For patients undergoing dental procedures in whom local bleeding must be controlled, tranexamic acid or epsilon amino caproic acid mouthwash can be administered without interrupting anticoagulant therapy (grade 2B).

### *Risk Factors for Adverse Events (Hemorrhage)*

1. For individuals who are otherwise good candidates for anticoagulation therapy, do not withhold therapy because of a patient's age (grade 1C).
2. Monitor elderly patients more carefully to maximize the TTR.

### *Models of Anticoagulation Management*

1. In comparing UC with AMS, we recommend that clinicians employ a systematic process to manage oral anticoagulation dosing that includes a knowledgeable provider, reliable PT monitoring, and an organized system of follow-up, patient communication, and education (grade 1C).
2. POC PST is for selected individuals who are willing and able to perform self-testing and are suitably trained. We recommend this model as an alternative to a UC model of INR monitoring and management to achieve a greater TTR (grade 2B).
3. Computer software programs for dose management must be considered individually based on well-designed clinical outcome studies. We recommend consideration of those software programs demonstrated to provide dosing decisions equivalent to a better than physician management, especially in high-volume anticoagulation programs (grade 2B).

## REFERENCES

- 1 Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. *Arch Intern Med* 1994; 154: 1443-1448
- 2 Dalen JE, Hirsh J. Fifth ACCP Consensus Conference on Antithrombotic Therapy. *Chest* 1998; 114(suppl):439S-769S
- 3 Hirsh J, Poller L. The international normalized ratio: a guide to understanding and correcting its problems. *Arch Intern Med* 1994; 154:282-288
- 4 Hull R, Hirsh J, Jay R, et al. Different intensities of oral

- anticoagulant therapy in the treatment of proximal-vein thrombosis. *N Engl J Med* 1982; 307:1676–1681
- 5 Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. *Lancet* 1988; 1:1242–1245
  - 6 Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. *N Engl J Med* 1990; 322:428–432
  - 7 Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. *J Thorac Cardiovasc Surg* 1991; 101:427–431
  - 8 Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med* 1994; 120:897–902
  - 9 Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1996; 335:540–546
  - 10 Cannegieter SC, Rosendaal FR, Wintzen AR, et al. The optimal intensity of oral anticoagulant therapy in patients with mechanical heart valve prostheses: the Leiden artificial valve and anticoagulation study. *N Engl J Med* 1995; 333:11–17
  - 11 European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. *N Engl J Med* 1995; 333:5–10
  - 12 Fihn SD, McDonnell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. *Ann Intern Med* 1993; 118:511–520
  - 13 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *Am J Med* 1989; 87:144–152
  - 14 Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remedial lesions. *Am J Med* 1989; 87:153–159
  - 15 Hirsh J, Dalen JE, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. *Chest* 1998; 114(suppl):445S–469S
  - 16 Kirkwood TBL. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. *Thromb Haemost* 1983; 49:238–244
  - 17 Ansell JE. Anticoagulation management as a risk factor for adverse events: grounds for improvement. *J Thromb Thrombolysis* 1998; 5(suppl):S13–S18
  - 18 Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results from a review of medical records from two communities. *Arch Intern Med* 2000; 160:967–973
  - 19 Ansell JE. The quality of anticoagulation management. *Arch Intern Med* 2000; 160:895–896
  - 20 O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy with a loading dose. *Circulation* 1968; 38:169–177
  - 21 Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy. *Ann Intern Med* 1997; 126:133–136
  - 22 Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. *Ann Intern Med* 1992; 116:901–904
  - 23 Redwood M, Taylor C, Bain BJ. The association of age with dosage requirement for warfarin. *Age Ageing* 1991; 20:217–220
  - 24 James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. *J Clin Pathol* 1992; 45:704–706
  - 25 Mungall D, White R. Aging and warfarin therapy. *Ann Intern Med* 1992; 117:878–879
  - 26 Bowles SK. Stereoselective disposition of warfarin in young and elderly subjects. *Clin Pharmacol Ther* 1994; 55:172
  - 27 McCormick D, Gurwitz JH, Goldberg J, et al. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use. *J Thromb Thrombolysis* 1999; 7:157–163
  - 28 Breckenridge AM. Interindividual differences in the response to oral anticoagulants. *Drugs* 1977; 14:367–375
  - 29 White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. *Ann Intern Med* 1995; 122:40–42
  - 30 Lousberg TR, Witt DM, Beall DG, et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. *Arch Intern Med* 1998; 158:528–534
  - 31 Shetty HG, Backhouse G, Bentley OP, et al. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K<sub>1</sub>. *Thromb Haemost* 1992; 67:13–15
  - 32 Martin JC. Anaphylactoid reactions and vitamin K [letter]. *Med J Aust* 1991; 155:851
  - 33 Whitting AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. *Arch Intern Med* 1998; 158:2136–2140
  - 34 Raj G, Kumar R, McKinney P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. *Arch Intern Med* 1999; 159:2721–2724
  - 35 Pengo V, Banzato A, Garelli E, et al. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K<sub>1</sub>) compared with warfarin discontinuation. *Blood Coagul Fibrinolysis* 1993; 4:739–741
  - 36 Cosgriff SW. The effectiveness of an oral vitamin K<sub>1</sub> in controlling excessive hypoprothrombinemia during anticoagulant therapy. *Ann Intern Med* 1956; 45:12–22
  - 37 Shirger A, Spittel JA, Ragen PA. Small doses of vitamin K<sub>1</sub> for correction of reduced prothrombin activity. *Proc Mayo Clin* 1959; 34:453–458
  - 38 Weibert RE, Le DT, Kayser SR, et al. Correction of excessive anticoagulation with low dose oral vitamin K<sub>1</sub>. *Ann Intern Med* 1997; 125:959–962
  - 39 Crowther MA, Donovan D, Harrison L, et al. Low dose oral vitamin K reliably reverses over anticoagulation due to warfarin. *Thromb Haemost* 1998; 79:1116–1118
  - 40 Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. *N Engl J Med* 1997; 336:1506–1511
  - 41 Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin. *Thromb Haemost* 1999; 82(suppl):62–63
  - 42 Tinnmouth A, Kovacs MJ, Cruickshank M, et al. Outpatient peri-operative and peri-procedure treatment with dalteparin for chronically anticoagulated patients at high risk for thromboembolic complications. *Thromb Haemost* 1999; 82(suppl):662
  - 43 Spandorfer JM, Lynch S, Weitz HH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. *Am J Cardiol* 1999; 84:478–480
  - 44 Wahl MJ. Dental surgery in anticoagulated patients. *Arch Intern Med* 1998; 158:1610–1616
  - 45 Sindet-Pedersen S, Ramstrom G, Bernvil S, et al. Hemostatic effect of tranexamic mouthwash in anticoagulant-treated patients undergoing oral surgery. *N Engl J Med* 1989; 324:840–843
  - 46 Souto JC, Oliver A, ZuaZu-Jausoro I, et al. Oral surgery in

- anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. *J Oral Maxillofac Surg* 1996; 54:27–32
- 47 van der Meer FJM, Rosendaal FR, vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. *Arch Intern Med* 1993; 153:1557–1562
  - 48 Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction: second report of the Sixty Plus Reinfarction Study Research Group. *Lancet* 1982; 1:62–68
  - 49 Pettiti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. *Am J Med* 1986; 81: 255–259
  - 50 White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. *Arch Intern Med* 1996; 156:1197–1201
  - 51 Beyth RJ, Quinn LM, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am J Med* 1998; 105: 91–99
  - 52 Laumbjerg J, Egeblad H, Heaf J, et al. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. *J Intern Med* 1991; 229:351–355
  - 53 Cortelazzo S, Finazzi G, Viero P, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. *Thromb Haemost* 1993; 69:316–320
  - 54 Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). *Lancet* 1996; 348:423–428
  - 55 Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, Minnesota. *Mayo Clin Proc* 1995; 70:725–733
  - 56 Landefeld S, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. *Am J Med* 1993; 95:315–328
  - 57 Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. *Am Heart J* 1982; 103:445–446
  - 58 Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. *Arch Intern Med* 1984; 144:1966–1968
  - 59 Petty GW, Lennihan L, Mohr JP, et al. Complications of long-term anticoagulation. *Ann Neurol* 1988; 23:570–574
  - 60 Charney R, Leddomado E, Rose DN, et al. Anticoagulation clinics and the monitoring of anticoagulant therapy. *Int J Cardiol* 1988; 18:197–206
  - 61 Bussey HI, Rospond RM, Quandt CM, et al. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. *Pharmacotherapy* 1989; 9:214–219
  - 62 Gurwitz J, Goldberg R, Holden A, et al. Age-related risks of long-term oral anticoagulant therapy. *Arch Intern Med* 1988; 148:1733–1736
  - 63 McInnes GT, Helenglass G. The performance of clinics for outpatient control of anticoagulation. *J R Coll Physicians Lond* 1987; 21:42–45
  - 64 Wickramasinghe LSP, Basu SK, Bansal SK. Long-term oral anticoagulant therapy in elderly patients. *Age Ageing* 1988; 17:388–396
  - 65 Joglekar M, Mohanaruban K, Bayer AJ, et al. Can old people on oral anticoagulants be safely managed as outpatients? *Postgrad Med J* 1988; 64:775–777
  - 66 Issacs C, Paltiel O, Blake G, et al. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture. *Am J Med* 1994; 96:487–491
  - 67 Davis FB, Estruch MT, Samson-Cervera EB, et al. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. *Arch Intern Med* 1977; 137:197–202
  - 68 Coon WW, Willis PW. Hemorrhagic complications of anticoagulant therapy. *Arch Intern Med* 1974; 133:386–392
  - 69 Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. *Arch Intern Med* 1996; 156:409–416
  - 70 Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complication in elderly patients treated with warfarin. *Ann Intern Med* 1996; 124:970–979
  - 71 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. *Lancet* 1996; 348:633–638
  - 72 Pettiti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. *Am J Med* 1986; 81:255–259
  - 73 Gurwitz JH, Goldberg RJ, Holden A, et al. Age related risks of long-term oral anticoagulant therapy. *Arch Intern Med* 1988; 148:1733–1736
  - 74 Wilson DB, Dunn MI, Hassanein K. Low intensity anticoagulation in mechanical cardiac prosthetic valves. *Chest* 1991; 100:1553–1557
  - 75 Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. *N Engl J Med* 1992; 327:1406–1412
  - 76 Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990; 323:1505–1511
  - 77 Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. *J Am Coll Cardiol* 1991; 18:349–355
  - 78 Petersen P, Boysan G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. *Lancet* 1989; 1:175–179
  - 79 Duxbury BMCD. Therapeutic control of anticoagulant treatment. *BMJ* 1982; 284:702–704
  - 80 Hutten BA, Prins MH, Redekop WK, et al. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. *Thromb Haemost* 1999; 82:1260–1263
  - 81 Rosendaal FR, Cannegieter SC, van der Meer FJM, et al. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost* 1993; 39:236–239
  - 82 Garabedian-Ruffalo SM, Gray DR, Sax MJ, et al. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. *Am J Hosp Pharm* 1985; 42:304–308
  - 83 Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? *Arch Intern Med* 1994; 154:1945–1953
  - 84 Holm T, Lassen JF, Husted SE, et al. Identification and surveillance of patient on oral anticoagulant therapy in a large geographic area-use of laboratory information systems. *Thromb Haemost* 1999; 82(suppl):858–859
  - 85 Beyth RJ, Landefeld CS. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial [abstract]. *J Gen Intern Med* 1997; 12:66
  - 86 Horstkotte D, Piper C, Wiemer M, et al. Improvement of



- prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy [abstract]. *Eur Heart J* 1996; 17(suppl):230
- 87 Sawicki PT. A structured teaching and self-management program for patient receiving oral anticoagulation: a randomized controlled trial: Working Group for the Study of Patient Self-Management of Oral Anticoagulation. *JAMA* 1999; 281:145-150
  - 88 Lundstrom T, Ryden L. Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. *J Intern Med* 1989; 225:137-142
  - 89 White RH, McCurdy A, Marensdorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. *Ann Intern Med* 1989; 111:730-737
  - 90 Ansell J, Patel N, Ostrovsky D, et al. Long-term patient self-management of oral anticoagulation. *Arch Intern Med* 1995; 155:2185-2189
  - 91 Conte RR, Kehoe WA, Nielson N, et al. Nine-year experience with a pharmacist-managed anticoagulation clinic. *Am J Hosp Pharm* 1986; 43:2460-2464
  - 92 Seabrook GR, Karp D, Schmitt DD, et al. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. *Am J Surg* 1990; 160:501-504
  - 93 Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. *Circulation* 1991; 84:527-539
  - 94 Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. *Lancet* 1994; 343:687-691
  - 95 Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients treated with atrial fibrillation: the AFASAK 2 study. *Arch Intern Med* 1999; 159:1322-1328
  - 96 European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. *Lancet* 1993; 342:1255-1262
  - 97 Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin. *BMJ* 1999; 319:958-964
  - 98 Kent DL, Domokos V, McDonell M, et al. A model for planning optimal follow-up for outpatients on warfarin anticoagulation. *Med Decis Making* 1992; 12:132-141
  - 99 Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. *J Thromb Thrombolysis* 1998; 5:S19-S24
  - 100 Verhagen H. Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl. *Acta Med Scand* 1954; 148:455-467
  - 101 Weinberg AC, Lieskovsky G, McGehee WG, et al. Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia. *J Urol* 1983; 130:352-354
  - 102 Broekmans AW, Bertina RM, Loeliger EA, et al. Protein C and the development of skin necrosis during anticoagulant therapy. *Thromb Haemost* 1983; 49:244-251
  - 103 Zauber NP, Stark MW. Successful warfarin anticoagulant despite protein C deficiency and a history of warfarin necrosis. *Ann Intern Med* 1986; 104:659-660
  - 104 Samama M, Horellou MH, Soria J, et al. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment. *Thromb Haemost* 1984; 51:332-333
  - 105 Grimaudo V, Gueissaz F, Hauert J, et al. Necrosis of skin induced by coumarin in a patient deficient in protein S. *BMJ* 1989; 298:233-234
  - 106 Fairweather RB, Ansell J, van den Besselaar AMHP, et al. Laboratory monitoring of oral anticoagulant therapy. *Arch Pathol Lab Med* 1998; 122:768-781
  - 107 Jaffin BW, Bliss CM, Lamont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. *Am J Med* 1987; 83:269-272
  - 108 Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. *Am J Med* 1988; 84:683-690
  - 109 Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. *Arch Intern Med* 1994; 154:649-652
  - 110 Caralis P, Gelbard M, Washer J, et al. Incidence and etiology of hematuria in patients on anticoagulant therapy [abstract]. *Clin Res* 1989; 37:791A
  - 111 Schuster GA, Lewis GA. Clinical significance of hematuria in patients on anticoagulant therapy. *J Urol* 1987; 137:923-925
  - 112 van Savage JG, Fried FA. Anticoagulant associated hematuria: a prospective study. *J Urol* 1995; 153:1594-1596
  - 113 ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. *Lancet* 1994; 343:499-503
  - 114 Stroke Prevention in Reversible Ischemia Trial (SPIRIT) study group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. *Ann Neurol* 1997; 42:857-865
  - 115 Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. *Am Heart J* 1996; 132:1095-1100
  - 116 Loeliger EA, van Dijk-Wierda CA, van den Besselaar AMHP, et al. Anticoagulant control and the risk of bleeding. In: Meade TW, ed. *Anticoagulants and myocardial infarction: a reappraisal*. New York, NY: John Wiley & Sons, 1984; 135-177
  - 117 Palareti G, Manotti C, D'Angelo A, et al. Thrombotic events during anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. *Thromb Haemost* 1997; 78:1438-1443
  - 118 Wilt VM, Gums JG, Ahmed OI, et al. Pharmacy operated anticoagulation service: improved outcomes in patients on warfarin. *Pharmacotherapy* 1995; 15:732-779
  - 119 Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. *Arch Intern Med* 1998; 158:1641-1647
  - 120 Matchar DB, Samsa GP, Cohen SJ, et al. The community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST). *J Thromb Thrombolysis* 2000; 9(suppl):S7-S12
  - 121 Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost justification of a clinical pharmacist-managed anticoagulation clinic. *Drug Intell Clin Pharm* 1985; 19:575-580
  - 122 Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management. *J Thromb Thrombolysis* 1996; 3:377-383
  - 123 Lucas FV, Duncan A, Jay R, et al. A novel whole blood capillary technique for measuring prothrombin time. *Am J Clin Pathol* 1987; 88:442-446
  - 124 Yano Y, Kambayashi J, Murata K, et al. Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor. *Thromb Res* 1992; 66:583-590
  - 125 Weibert RT, Adler DS. Evaluation of a capillary whole blood prothrombin time measurement system. *Clin Pharm* 1989; 8:864-867

- 126 Jennings I, Luddington RJ, Baglin T. Evaluation of the Cibra Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation. *J Clin Pathol* 1991; 44:950–953
- 127 McCurdy SA, White RH. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. *Arch Intern Med* 1992; 152:589–592
- 128 Tripodi A, Arbini AA, Chantarangkul V, et al. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio? *Thromb Haemost* 1993; 70:921–924
- 129 Oberhardt BJ, Dermott SC, Taylor M, et al. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. *Clin Chem* 1991; 37:520–526
- 130 Rose VL, Dermott SC, Murray BF, et al. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer. *Arch Pathol Lab Med* 1993; 117:611–617
- 131 Fabbrini N, Messmore H, Balbale S, et al. Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting [abstract]. *Blood* 1995; 86(suppl):869a
- 132 Tripodi A, Chantarangkul V, Clerici M, et al. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy. *Thromb Haemost* 1997; 78:855–858
- 133 Kaatz AA, White RH, Hill J, et al. Accuracy of laboratory and portable monitor international normalized ratio determinations. *Arch Intern Med* 1995; 155:1861–1867
- 134 Ansell J, Becker D, Andrew M, et al. Accurate and precise prothrombin time measurement in a multicenter anticoagulation trial employing patient self-testing [abstract]. *Blood* 1995; 86(suppl):864a
- 135 Andrew M, Marzinotto V, Adams M, et al. Monitoring of oral anticoagulant therapy in pediatric patients using a new micro-sample PT device [abstract]. *Blood* 1995; 86(suppl):863a
- 136 Ansell JE, Zweig S, Meyer B, et al. Performance of the Avocet<sub>PT</sub> prothrombin time system [abstract]. *Blood* 1998; 92(suppl):112b
- 137 WHO Tech Rep Ser 1999; 889:64–80
- 138 Sickles J, Elston-Lafata J, Ansell J. Point-of-care testing in coagulation and hemostasis: implications for patient management. *Dis Manage Health Outcomes* 1999; 6:291–301
- 139 Anderson D, Harrison L, Hirsh L. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. *Arch Intern Med* 1993; 153:1441–1447
- 140 Andrew M, Ansell J, Becker D, et al. Multicenter trial of accurate home self-testing in oral anticoagulant patients with a novel whole blood system. *Blood* 1996; 88(suppl):179a
- 141 Erdman S, Vidne B, Levy MJ. A self-control method for long-term anticoagulation therapy. *J Cardiovasc Surg* 1974; 15:454–457
- 142 Ansell J, Holden A, Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. *Arch Intern Med* 1989; 149:2509–2511
- 143 Bernardo A. Experience with patient self-management of oral anticoagulation. *J Thromb Thrombolysis* 1996; 2:321–325
- 144 Hasenkam JM, Kimose HH, Knudsen L, et al. Self-management of oral anticoagulant therapy after heart valve replacement. *Eur J Cardiothorac Surg* 1997; 11:935–942
- 145 Koertke H, Minami K, Breyman T, et al. INR self-management following mechanical heart valve replacement: are education level and therapeutic compliance connected? *J Thromb Thrombolysis* 2000; 9(suppl):S41–S46
- 146 Wilson R, James AH. Computer assisted management of warfarin treatment. *BMJ* 1984; 289:422–424
- 147 Ryan PJ, Gilbert M, Rose PE. Computer control of anticoagulant dose for therapeutic management. *BMJ* 1989; 299:1207–1209
- 148 Weston Smith SG, Savidge GF. Computer control of anticoagulant dose [letter]. *BMJ* 1989; 299:1529
- 149 Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. *J Clin Pathol* 1993; 46:299–303
- 150 Ageno W, Turpie AGG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. *J Thromb Thrombolysis* 1998; 5(suppl):S69
- 151 Poller L, Shiach CR, MacCallum P, et al. The European Concerted Action on Anticoagulation (ECAA): multicentre randomized study of computerized anticoagulant dosage. *Lancet* 1998; 352:1505–1509
- 152 Hall JC, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. *Am J Med* 1980; 68:122–140
- 153 Vitale N, DeFeo M, Salvatore L, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. *J Am Coll Cardiol* 1999; 33:1637–1641
- 154 Gohlke-Varwolf C, Acar J, Oakley CM, et al. Guidelines for prevention of thromboembolic events in valvular heart disease. *Eur Heart J* 1995; 16:1320–1330
- 155 Salazar E, Izagurine R, Verdejo J, et al. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. *J Am Coll Cardiol* 1996; 27:1698–1713
- 156 Sanson BJ, Lensing AWA, Prins MH, et al. Safety of low molecular weight heparin in pregnancy: a systematic review. *Thromb Haemost* 1999; 81:668–672
- 157 Lao TT, DeSwiet M, Letsky R, et al. Prophylaxis of thromboembolism in pregnancy: an alternative. *Br J Obstet Gynaecol* 1985; 92:202–206
- 158 McKenna R, Cale ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? *J Pediatr* 1983; 103:325–327
- 159 Rosove MH, Brever PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. *Ann Intern Med* 1992; 117:303–308
- 160 Khamashta ML, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med* 1995; 332:993–997
- 161 Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. *Ann Intern Med* 1997; 127:177–185
- 162 Della Valle P, Crippa L, Safa O, et al. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. *Ann Med Interne (Paris)* 1996; 147(suppl):10–14
- 163 Rapaport SI, Le DT. Thrombosis in the antiphospholipid antibody syndrome [letter]. *N Engl J Med* 1995; 333:665
- 164 Lawrie AS, Purdy G, Mackie IJ, et al. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. *Br J Haematol* 1997; 98:887–892
- 165 Rapaport SI, Le DT. Thrombosis in the antiphospholipid antibody syndrome [letter]. *N Engl J Med* 1995; 333:665
- 166 Le DT, Weibert RT, Sevilla BK, et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. *Ann Intern Med* 1994; 120:552–558
- 167 Lind SE, Callas PW, Golden EA, et al. Plasma levels of factors II, VII, and X and their relationship to the international normalized ratio during chronic warfarin therapy. *Blood Coagul Fibrinolysis* 1997; 8:48–53
- 168 Kornbert A, Frances DW, Pellegrini VD Jr, et al. Comparison of native prothrombin antigen with prothrombin time for monitoring oral anticoagulant prophylaxis. *Circulation* 1993; 88:454–460

## Managing Oral Anticoagulant Therapy

Jack Ansell, Jack Hirsh, James Dalen, Henry Bussey, David Anderson, Leon Poller,  
Alan Jacobson, Daniel Deykin and David Matchar

*Chest* 2001;119;22-38

DOI: 10.1378/chest.119.1\_suppl.22S

**This information is current as of June 29, 2005**

<b>Updated Information &amp; Services</b>	Updated information and services, including high-resolution figures, can be found at: <a href="http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S">http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S</a>
<b>References</b>	This article cites 165 articles, 64 of which you can access for free at: <a href="http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S#BIBL">http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S#BIBL</a>
<b>Citations</b>	This article has been cited by 41 HighWire-hosted articles: <a href="http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S#otherarticles">http://www.chestjournal.org/cgi/content/full/119/1_suppl/22S#otherarticles</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.chestjournal.org/misc/reprints.shtml">http://www.chestjournal.org/misc/reprints.shtml</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://www.chestjournal.org/misc/reprints.shtml">http://www.chestjournal.org/misc/reprints.shtml</a>
<b>Email alerting service</b>	Receive free email alerts when new articles cite this article sign up in the box at the top right corner of the online article.
<b>Images in PowerPoint format</b>	Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online article figure for directions.

